{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:46:10Z","timestamp":1792226770264,"version":"4.4.0"},"reference-count":181,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic sclerosis (SSc) is a rare autoimmune disease characterized by a tripod combining vasculopathy, fibrosis, and immune-mediated inflammatory processes. The prevalence of interstitial lung disease (ILD) in SSc varies according to the methods used to detect it, ranging from 25 to 95%. The fibrotic and vascular pulmonary manifestations of SSc, particularly ILD, are the main causes of morbidity and mortality, contributing to 35% of deaths. Although early trials were conducted with cyclophosphamide, more recent randomized controlled trials have been performed to assess the efficacy and tolerability of several medications, mostly mycophenolate, rituximab, tocilizumab, and nintedanib. Although many uncertainties remain, expert consensus is emerging to optimize the therapeutic management and to provide clinicians with evidence-based clinical practice guidelines for patients with SSc-ILD. This article provides an overview, in the light of the latest advances, of the available evidence for the diagnosis and management of SSc-ILD.<\/jats:p>","DOI":"10.1055\/s-0044-1786698","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T23:02:09Z","timestamp":1715122929000},"page":"342-364","source":"Crossref","is-referenced-by-count":13,"title":["Interstitial Lung Disease Associated with Systemic Sclerosis"],"prefix":"10.1055","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1586-047X","authenticated-orcid":false,"given":"Valentine","family":"Mismetti","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Coordinating Reference Centre for Rare Pulmonary Diseases, ERN-LUNG, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0314-4010","authenticated-orcid":false,"given":"Salim","family":"Si-Mohamed","sequence":"additional","affiliation":[{"name":"INSA-Lyon, University of Lyon, University Claude-Bernard Lyon 1, Lyon, France"},{"name":"Radiology Department, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Coordinating Reference Centre for Rare Pulmonary Diseases, ERN-LUNG, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France"},{"name":"UMR 754, INRAE, Claude Bernard University Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"E R Volkmann","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"A J Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"M Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"A M Hoffmann-Vold","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000592","article-title":"Management of systemic sclerosis-associated interstitial lung disease","volume":"31","author":"D Roofeh","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"S I Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"V D Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"M Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"699532","DOI":"10.3389\/fmed.2021.699532","article-title":"Epidemiology, mortality and healthcare resource utilization associated with systemic sclerosis-associated interstitial lung disease in France","volume":"8","author":"V Cottin","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/23120541.00309-2019","article-title":"Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA","volume":"6","author":"P Ratanawatkul","year":"2020","journal-title":"ERJ Open Res"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database","volume":"66","author":"U A Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1016\/S2665-9913(22)00217-X","article-title":"Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort","volume":"4","author":"M Elhai","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/art.34482","article-title":"A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis","volume":"64","author":"V Steen","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"02","key":"ref14","first-page":"177","article-title":"Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes","volume":"1","author":"C Peoples","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s10067-021-05997-w","article-title":"Gender differences in clinical features and outcomes of a Portuguese systemic sclerosis cohort","volume":"41","author":"R Freitas","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"08","key":"ref16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2023.1729","article-title":"Cutaneous manifestations, clinical characteristics, and prognosis of patients with systemic sclerosis sine scleroderma: data from the International EUSTAR database","volume":"159","author":"A Lescoat","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/ije\/dyaa287","article-title":"Occupational exposure to respirable crystalline silica and risk of autoimmune rheumatic diseases: a nationwide cohort study","volume":"50","author":"S H Boudigaard","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1093\/rheumatology\/keaa446","article-title":"Occupational silica exposure in an Australian systemic sclerosis cohort","volume":"59","author":"S Patel","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s10067-018-4045-y","article-title":"High prevalence of occupational exposure to solvents or silica in male systemic sclerosis patients: a Belgian cohort analysis","volume":"37","author":"E De Decker","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaad.2014.11.027","article-title":"Association of occupational exposure with features of systemic sclerosis","volume":"72","author":"I Marie","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/rccm.201905-1057LE","article-title":"Silica exposure and connective tissue disease: an underrecognized association in three Australian artificial stone workers","volume":"201","author":"M T Turner","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.autrev.2013.10.002","article-title":"Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature","volume":"13","author":"I Marie","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/RHU.0000000000000354","article-title":"The influence of different solvents on systemic sclerosis: an updated meta-analysis of 14 case-control studies","volume":"22","author":"J H Zhao","year":"2016","journal-title":"J Clin Rheumatol"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.semarthrit.2020.08.014","article-title":"Association of silica exposure with chest HRCT and clinical characteristics in systemic sclerosis","volume":"50","author":"A Ballerie","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"09","key":"ref25","first-page":"1713","article-title":"Relationship between occupational risk factors and severity markers of systemic sclerosis","volume":"32","author":"J Magnant","year":"2005","journal-title":"J Rheumatol"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.chest.2021.11.009","article-title":"Independent association between occupational exposure and decline of FVC in systemic sclerosis: a multicenter recruitment retrospective cohort study","volume":"161","author":"B Thoreau","year":"2022","journal-title":"Chest"},{"issue":"7835","key":"ref27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"N C Henderson","year":"2020","journal-title":"Nature"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"M Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1183\/13993003.00075-2020","article-title":"The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops","volume":"56","author":"A R Rackow","year":"2020","journal-title":"Eur Respir J"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MCP.0b013e328363f4de","article-title":"Extracellular matrix microenvironment contributes actively to pulmonary fibrosis","volume":"19","author":"C Shimbori","year":"2013","journal-title":"Curr Opin Pulm Med"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1183\/13993003.04507-2020","article-title":"When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases","volume":"58","author":"M Selman","year":"2021","journal-title":"Eur Respir J"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"A Perelas","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/BOR.0b013e32834b1606","article-title":"New insights on chemically induced animal models of systemic sclerosis","volume":"23","author":"F Batteux","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"933468","DOI":"10.3389\/fimmu.2022.933468","article-title":"Role of B-cell in the pathogenesis of systemic sclerosis","volume":"13","author":"B Thoreau","year":"2022","journal-title":"Front Immunol"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0394632015572750","article-title":"From microvasculature to fibroblasts: contribution of anti-endothelial cell antibodies in systemic sclerosis","volume":"28","author":"C Corallo","year":"2015","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis","volume":"60","author":"J F Classen","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"65","author":"F van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000440665","article-title":"Interstitial lung disease evaluation: detecting connective tissue disease","volume":"90","author":"A Fischer","year":"2015","journal-title":"Respiration"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3899\/jrheum.140236","article-title":"Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects","volume":"41","author":"S Diab","year":"2014","journal-title":"J Rheumatol"},{"issue":"25","key":"ref40","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"D P Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease","volume":"67","author":"Y A Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"A M Hoffmann-Vold","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/BOR.0000000000000323","article-title":"Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis","volume":"28","author":"\u00d8 Molberg","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/art.41415","article-title":"Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis","volume":"72","author":"E J Bernstein","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/art.39528","article-title":"Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension","volume":"68","author":"K M Antoniou","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"07","key":"ref46","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/art.21131","article-title":"The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study)","volume":"52","author":"F M Wigley","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.semarthrit.2018.10.011","article-title":"Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality","volume":"49","author":"N Champtiaux","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"ref48","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"N S Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/23971983211064463","article-title":"Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography","volume":"7","author":"D Khanna","year":"2022","journal-title":"J Scleroderma Relat Disord"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1148\/radiol.2322031223","article-title":"CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia","volume":"232","author":"S R Desai","year":"2004","journal-title":"Radiology"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.rti.0000213572.16904.40","article-title":"Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis","volume":"22","author":"R M Shah","year":"2007","journal-title":"J Thorac Imaging"},{"issue":"09","key":"ref53","first-page":"1789","article-title":"High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis","volume":"33","author":"D Launay","year":"2006","journal-title":"J Rheumatol"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.07-2444","article-title":"High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease","volume":"134","author":"J G Goldin","year":"2008","journal-title":"Chest"},{"issue":"11","key":"ref55","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II","volume":"15","author":"J G Goldin","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/RTI.0000000000000319","article-title":"The four corners sign: a specific imaging feature in differentiating systemic sclerosis-related interstitial lung disease from idiopathic pulmonary fibrosis","volume":"33","author":"L Walkoff","year":"2018","journal-title":"J Thorac Imaging"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/resp.13175","article-title":"Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease","volume":"23","author":"R Takei","year":"2018","journal-title":"Respirology"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1007\/s00330-021-08482-9","article-title":"Automatic quantitative computed tomography measurement of longitudinal lung volume loss in interstitial lung diseases","volume":"32","author":"S A Si-Mohamed","year":"2022","journal-title":"Eur Radiol"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/RCT.0b013e3180690d89","article-title":"Selection of appropriate computed tomographic image reconstruction algorithms for a quantitative multicenter trial of diffuse lung disease","volume":"32","author":"J Zhang","year":"2008","journal-title":"J Comput Assist Tomogr"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/RCT.0b013e318181d551","article-title":"Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease","volume":"33","author":"J H Hwang","year":"2009","journal-title":"J Comput Assist Tomogr"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12890-022-01837-y","article-title":"Thoracic lymphadenopathies in diffuse systemic sclerosis: an observational study on 48 patients using computed tomography","volume":"22","author":"A Renaud","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"06","key":"ref62","doi-asserted-by":"crossref","first-page":"e0180283","DOI":"10.1371\/journal.pone.0180283","article-title":"Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease","volume":"12","author":"Y Enomoto","year":"2017","journal-title":"PLoS One"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"1902135","DOI":"10.1183\/13993003.02135-2019","article-title":"Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact","volume":"56","author":"M Bonifazi","year":"2020","journal-title":"Eur Respir J"},{"issue":"09","key":"ref64","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/art.34501","article-title":"Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension","volume":"64","author":"S G\u00fcnther","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1164\/rccm.202206-1041ST","article-title":"Syndrome of combined pulmonary fibrosis and emphysema: an official ATS\/ERS\/JRS\/ALAT research statement","volume":"206","author":"V Cottin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"e000820","DOI":"10.1136\/rmdopen-2018-000820","article-title":"Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis","volume":"5","author":"A Ariani","year":"2019","journal-title":"RMD Open"},{"issue":"05","key":"ref67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/13993003.04503-2020","article-title":"Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis","volume":"59","author":"J Schniering","year":"2022","journal-title":"Eur Respir J"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiol.2020200319","article-title":"Elastic registration-driven deep learning for longitudinal assessment of systemic sclerosis interstitial lung disease at CT","volume":"298","author":"G Chassagnon","year":"2021","journal-title":"Radiology"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.semarthrit.2008.10.009","article-title":"Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature","volume":"40","author":"O Kowal-Bielecka","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1164\/rccm.200705-655OC","article-title":"Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease","volume":"177","author":"C Strange","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref71","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/art.22696","article-title":"Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression","volume":"56","author":"N S Goh","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"ref72","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/art.23077","article-title":"Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease","volume":"56","author":"S Mittoo","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"03","key":"ref73","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/ard.60.3.281","article-title":"Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis","volume":"60","author":"J Fujita","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref74","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"D Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref75","first-page":"121","article-title":"The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia","volume":"19","author":"D S Kim","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2559.2008.03072.x","article-title":"Arterial and interstitial remodelling processes in non-specific interstitial pneumonia: systemic sclerosis versus idiopathic","volume":"53","author":"E F de Carvalho","year":"2008","journal-title":"Histopathology"},{"issue":"04","key":"ref77","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000156958","article-title":"Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis","volume":"77","author":"R B de Souza","year":"2009","journal-title":"Respiration"},{"issue":"08","key":"ref78","first-page":"1670","article-title":"Usual interstitial pneumonia is the predominant histopathology in patients with systemic sclerosis receiving a lung transplant","volume":"41","author":"E Valenzi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"01","key":"ref79","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12890-023-02429-0","article-title":"Can transbronchial lung cryobiopsy benefit adaptive treatment strategies in connective tissue disease-associated interstitial lung disease?","volume":"23","author":"H Yamakawa","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"12","key":"ref80","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/thorax-2023-220541","article-title":"Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis","volume":"78","author":"S Guler","year":"2023","journal-title":"Thorax"},{"issue":"12","key":"ref81","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/thorax-2023-220820","article-title":"Outcomes of systemic sclerosis associated interstitial lung disease patients with a persistent inflammatory phenotype based on serial CRP measurements","volume":"78","author":"E R Volkmann","year":"2023","journal-title":"Thorax"},{"issue":"01","key":"ref82","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"F F Rahaghi","year":"2023","journal-title":"Respir Res"},{"issue":"07","key":"ref83","first-page":"1081","article-title":"Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies","volume":"56","author":"I M Markusse","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"C P Denton","year":"2017","journal-title":"Lancet"},{"issue":"03","key":"ref85","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"S I Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"05","key":"ref86","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.40027","article-title":"Early mortality in a multinational systemic sclerosis inception cohort","volume":"69","author":"Y Hao","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"05","key":"ref87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"O Distler","year":"2020","journal-title":"Eur Respir J"},{"issue":"10","key":"ref88","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/art.30467","article-title":"Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group","volume":"63","author":"D Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"O A Moore","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"06","key":"ref90","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/rheumatology\/kew480","article-title":"Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis","volume":"56","author":"A Ariani","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"07","key":"ref91","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","article-title":"Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes","volume":"175","author":"J H Park","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref92","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.chest.2017.06.009","article-title":"Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model","volume":"152","author":"J Morisset","year":"2017","journal-title":"Chest"},{"issue":"05","key":"ref93","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.15-0003","article-title":"Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis","volume":"148","author":"C J Ryerson","year":"2015","journal-title":"Chest"},{"issue":"05","key":"ref94","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort","volume":"12","author":"S Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"09","key":"ref95","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"W Wu","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"01","key":"ref96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"E R Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"08","key":"ref97","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"N S Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"05","key":"ref98","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.chest.2021.11.033","article-title":"Early radiographic progression of scleroderma: lung disease predicts long-term mortality","volume":"161","author":"E R Volkmann","year":"2022","journal-title":"Chest"},{"issue":"12","key":"ref99","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00330-011-2223-2","article-title":"Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide","volume":"21","author":"H J Kim","year":"2011","journal-title":"Eur Radiol"},{"issue":"01","key":"ref100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1183\/13993003.01011-2016","article-title":"Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures","volume":"49","author":"J Jacob","year":"2017","journal-title":"Eur Respir J"},{"issue":"02","key":"ref101","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/RTI.0000000000000317","article-title":"Short-term automated quantification of radiologic changes in the characterization of idiopathic pulmonary fibrosis versus nonspecific interstitial pneumonia and prediction of long-term survival","volume":"33","author":"F De Giacomi","year":"2018","journal-title":"J Thorac Imaging"},{"issue":"09","key":"ref102","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/annrheumdis-2020-217359","article-title":"Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT","volume":"79","author":"M Occhipinti","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"03","key":"ref103","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1183\/13993003.01384-2018","article-title":"Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis","volume":"52","author":"S M Humphries","year":"2018","journal-title":"Eur Respir J"},{"issue":"02","key":"ref104","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1513\/AnnalsATS.202301-084OC","article-title":"Deep learning-based fibrosis extent on computed tomography predicts outcome of fibrosing interstitial lung disease independent of visually assessed computed tomography pattern","volume":"21","author":"A S Oh","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"171","key":"ref105","doi-asserted-by":"crossref","first-page":"230055","DOI":"10.1183\/16000617.0055-2023","article-title":"Towards the adoption of quantitative computed tomography in the management of interstitial lung disease","volume":"33","author":"S LF Walsh","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"08","key":"ref106","doi-asserted-by":"crossref","first-page":"e0181692","DOI":"10.1371\/journal.pone.0181692","article-title":"Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease","volume":"12","author":"N Le Gouellec","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"ref107","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"V D Steen","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"08","key":"ref108","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/rheumatology\/kev016","article-title":"Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling","volume":"54","author":"A Man","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"ref109","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"S A Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/rmdopen-2023-003658","article-title":"Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort","volume":"10","author":"M Scheidegger","year":"2024","journal-title":"RMD Open"},{"issue":"02","key":"ref111","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"A M Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"ref112","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1007\/s10067-020-05105-4","article-title":"Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment","volume":"39","author":"L Vanaken","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"06","key":"ref113","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.semarthrit.2021.08.001","article-title":"Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: a systematic review using the OMERACT filter 2.1 process","volume":"51","author":"D Roofeh","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"18","key":"ref114","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"K R Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"06","key":"ref115","doi-asserted-by":"crossref","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"K K Brown","year":"2020","journal-title":"Eur Respir J"},{"issue":"10","key":"ref116","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1164\/rccm.202206-1143LE","article-title":"Progressive pulmonary fibrosis: Should the timelines be taken out of the definition?","volume":"206","author":"V Cottin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref117","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society Clinical Practice Guideline","volume":"209","author":"G Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"ref118","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/thoraxjnl-2020-215918","article-title":"Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis","volume":"76","author":"S Liu","year":"2021","journal-title":"Thorax"},{"issue":"05","key":"ref119","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/resp.13988","article-title":"Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression","volume":"26","author":"C JW Stock","year":"2021","journal-title":"Respirology"},{"issue":"08","key":"ref120","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease","volume":"45","author":"G A Salazar","year":"2018","journal-title":"J Rheumatol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"220003","DOI":"10.1183\/16000617.0003-2022","article-title":"Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives","volume":"31","author":"V Cottin","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"12","key":"ref122","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"R K Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"ref123","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"D P Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"09","key":"ref124","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"D P Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"03","key":"ref125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"R Namas","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"04","key":"ref126","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.chest.2016.11.052","article-title":"Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of Scleroderma Lung Study II","volume":"151","author":"D P Tashkin","year":"2017","journal-title":"Chest"},{"issue":"06","key":"ref127","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr2.11125","article-title":"Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of Scleroderma Lung Study II","volume":"2","author":"E R Volkmann","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"07","key":"ref128","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II","volume":"69","author":"E R Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"ref129","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"G Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"A C Allison","year":"2000","journal-title":"Immunopharmacology"},{"issue":"02","key":"ref131","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"G SRSNK Naidu","year":"2020","journal-title":"Rheumatol Int"},{"issue":"01","key":"ref132","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"K B Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"D Khanna","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"ref134","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"D Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"06","key":"ref135","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"D Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref136","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/rmdopen-2022-002477","article-title":"Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort","volume":"8","author":"S Kuster","year":"2022","journal-title":"RMD Open"},{"issue":"02","key":"ref137","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"D Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"07","key":"ref138","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"S Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"01","key":"ref139","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"T M Maher","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"06","key":"ref140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"J Mankikian","year":"2023","journal-title":"Eur Respir J"},{"issue":"02","key":"ref141","doi-asserted-by":"crossref","first-page":"e000384","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in early systemic sclerosis","volume":"3","author":"M Boonstra","year":"2017","journal-title":"RMD Open"},{"issue":"02","key":"ref142","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"D Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"ref143","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"D Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"05","key":"ref144","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"D Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"09","key":"ref145","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"V D Steen","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"03","key":"ref146","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00296-010-1697-6","article-title":"Corticosteroids and the risk of scleroderma renal crisis: a systematic review","volume":"32","author":"G Trang","year":"2012","journal-title":"Rheumatol Int"},{"issue":"09","key":"ref147","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"G Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"ref148","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"L Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"ref149","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"O Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"04","key":"ref150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.41576","article-title":"Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial","volume":"73","author":"T M Maher","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"SI43","DOI":"10.1093\/rheumatology\/keac325","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"M Kreuter","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"05","key":"ref152","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/keac535","article-title":"Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial","volume":"62","author":"C P Denton","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"03","key":"ref153","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41965","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and modified Rodnan skin thickness score","volume":"74","author":"M Kuwana","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"ref154","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2665-9913(22)00215-6","article-title":"Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials","volume":"4","author":"A M Hoffmann-Vold","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"01","key":"ref155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/rmdopen-2022-002859","article-title":"Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression","volume":"9","author":"D Khanna","year":"2023","journal-title":"RMD Open"},{"issue":"11","key":"ref156","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","article-title":"Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial","volume":"79","author":"J R Seibold","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref157","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2022-222564","article-title":"Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON","volume":"81","author":"Y Allanore","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"ref158","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100\u2009weeks: data from a randomized controlled trial","volume":"4","author":"S Assassi","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"05","key":"ref159","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"A U Wells","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","article-title":"Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases","volume":"22","author":"V Cottin","year":"2021","journal-title":"Respir Res"},{"issue":"9779","key":"ref161","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"P W Noble","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"ref162","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"T E King Jr","year":"2014","journal-title":"N Engl J Med"},{"issue":"02","key":"ref163","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"T M Maher","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"05","key":"ref164","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"J Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref165","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"J J Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"09","key":"ref166","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"D Khanna","year":"2016","journal-title":"J Rheumatol"},{"issue":"01","key":"ref167","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"K M Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"ref168","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"J M van Laar","year":"2014","journal-title":"JAMA"},{"issue":"9790","key":"ref169","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"R K Burt","year":"2011","journal-title":"Lancet"},{"issue":"05","key":"ref170","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1164\/rccm.200808-1359OC","article-title":"Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring","volume":"179","author":"E Savarino","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref171","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"P O Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"ref172","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1164\/rccm.202009-3608ST","article-title":"Home oxygen therapy for adults with chronic lung disease. an official American Thoracic Society Clinical Practice Guideline","volume":"202","author":"S S Jacobs","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref173","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation","volume":"40","author":"L E Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"07","key":"ref174","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","article-title":"Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study","volume":"37","author":"P Prad\u00e8re","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.lpm.2014.01.020","article-title":"Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group","volume":"43","author":"D Launay","year":"2014","journal-title":"Presse Med"},{"issue":"S 01","key":"ref176","first-page":"e73","article-title":"[Lung transplantation for systemic sclerosis-associated interstitial lung disease]","volume":"40","author":"J Le Pavec","year":"2023","journal-title":"Rev Mal Respir"},{"issue":"01","key":"ref177","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice","volume":"74","author":"D Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"03","key":"ref178","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"S K Rajan","year":"2023","journal-title":"Eur Respir J"},{"issue":"12","key":"ref179","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Y Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref180","first-page":"12","article-title":"Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data","volume":"12","author":"E Fiorentini","year":"2022","journal-title":"Life (Basel)"},{"issue":"02","key":"ref181","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"J K Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"08","key":"ref182","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3899\/jrheum.191365","article-title":"STRATUS: a phase II study of abituzumab in patients with systemic sclerosis-associated interstitial lung disease","volume":"48","author":"D Khanna","year":"2021","journal-title":"J Rheumatol"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1786698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:35:38Z","timestamp":1730802938000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1786698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":181,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,5,22]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1786698","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]}}}